She is a recipient of the NMRC Senior Investigator Clinician Scientist Award, Programme Lead of A*STaR’s Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT), Principal Investigator of ASIAN-HF (multinational study across 11 Asian countries), & Executive Committee member/ lead of multiple global clinical trials. She is a world-renown clinical trialist, with her work as part of the global steering committee of the PARAGON trial contributing to the first FDA-approved treatment for HFpEF to date (Entresto Wins First FDA Nod in Hard-to-Treat Type of Heart Failure ()). Dr Lam is a Professor at Duke-National University of Singapore & Senior Consultant at the National Heart Centre Singapore specializing in heart failure & recognized globally for expertise in heart failure with preserved ejection fraction.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |